emerge and spread in society they become a major public health issue. AMR is an increasingly serious threat to global public health that requires action across all government sectors and society 4 .
In many cases the cost of healthcare for patients with resistant infections is higher due to longer duration of illness, additional medical/laboratory testing, and the use of more expensive drugs. As reported by Gilbert et 
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Extended-spectrum β-lactamases Cephalothin, Nalidixic acid, Gentamicin For many clinicians, the threat of AMR is becoming a reality both in the community and in the hospital setting, a worrisome situation experienced in the pre-antibiotic era.
AMR and no new antimicrobial discoveries
Many antibiotics used today are the result of scientific discoveries from many years ago In 2017 the WHO published its first ever list of antibiotic-resistant 'priority pathogens' -a catalogue of 12 families of bacteria that pose the greatest threat to human health.
WHO priority pathogens list for research and development of new antibiotics 
AMR and primary health care in hospitals and community
Antimicrobial use and AMR is one of the most pressing problems faced in healthcare services. Antimicrobial use and overuse is also a concern in the community and is rising steadily globally In Focus
